Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products

4/2/2026

Fact Sheets

View Original

Action Summary

Purpose: Bolster national security and public health by reducing reliance on imported patented pharmaceuticals and ingredients.
Tariff Impositions:
- 100% tariff on patented pharmaceutical products and ingredients.
- Tariff schedules: 120 days for large companies; 180 days for smaller companies.
Trade Deal Adjustments:
- 15% tariff applies for products from the EU, Japan, Korea, Switzerland, and Liechtenstein.
- Lower tariff for products from the United Kingdom subject to a new UK pharmaceutical agreement.
Onshoring and Pricing Agreements:
- 0% tariff for companies entering Most Favored Nation (MFN) pricing agreements with HHS and onshoring agreements with the Department of Commerce until January 20, 2029.
- 20% tariff for companies with only onshoring agreements.
Exemptions:
- Generic pharmaceuticals, biosimilars, and associated ingredients are exempt (to be reassessed in one year).
- Exemptions also apply to specialty pharmaceuticals such as orphan drugs and drugs for animal health if from trade deal countries or meeting urgent public health needs.
Monitoring and Enforcement: Establishes robust monitoring measures including external audits and provisions for increasing tariffs on future and past imports.
Investigation Findings and Economic Impact:
- Section 232 investigation revealed that the volume of imported patented pharmaceuticals threatens national security.
- Resulted in approximately $400 billion in new domestic investment commitments from U.S. and foreign pharmaceutical companies.
Strategic Policy Alignment:
- Builds upon prior Executive Orders aimed at removing regulatory barriers and reestablishing a robust domestic manufacturing base for pharmaceuticals.
- Extends Section 232 investigations to related sectors such as personal protective equipment, medical consumables, and medical devices to protect overall national security.

Risks & Considerations

The imposition of tariffs on patented pharmaceuticals by President Trump could significantly impact the pharmaceutical supply chain, potentially leading to increased costs for essential medicines. This may affect Vanderbilt University’s ability to procure necessary pharmaceutical products for research and healthcare services.
As Vanderbilt University Medical Center (VUMC) engages in pharmaceutical research and clinical trials, the tariffs might lead to increased operational costs, which could strain budgets and impact research funding and availability of medications for patients.
There is a risk that the tariffs could create supply chain disruptions, particularly if foreign manufacturers and suppliers are unable or unwilling to absorb the additional costs. This could lead to shortages of critical medications, which may affect the university’s healthcare services.
The potential for increased tariffs on pharmaceutical products may compel VUMC to reevaluate its vendor relationships and supply chain strategies, leading to possible delays in research and patient care. Furthermore, ongoing investigations into funding practices may compound these challenges, creating uncertainties in financial planning.

Impacted Programs

Vanderbilt University Medical Center will need to closely monitor the implications of these tariffs on its procurement processes and patient care protocols, which could lead to changes in how they source pharmaceuticals and manage related budgets.
Vanderbilt’s Research Departments may face limitations in accessing necessary materials for ongoing research, particularly in biomedical fields that rely heavily on imported pharmaceutical ingredients.
The Department of Pharmaceutical Sciences should prepare for the potential need to adapt its curriculum or research focus in response to the shifting pharmaceutical landscape and the impacts of tariffs on drug availability and pricing.
Vanderbilt’s Health Policy Program may need to engage in advocacy efforts to address the implications of these tariffs on healthcare access and affordability, ensuring that the university’s voice is heard in discussions about national health policy.

Financial Impact

The introduction of significant tariffs could lead to increased costs for pharmaceutical companies, which may be passed on to healthcare providers like VUMC. This could necessitate adjustments in budget allocations and financial planning.
Vanderbilt University may face challenges in securing federal grants and funding due to the potential perception of instability in the pharmaceutical sector, particularly if these tariffs lead to a decrease in research output or innovation.
As pharmaceutical companies respond to tariffs by altering their pricing or supply strategies, there may be fluctuations in funding opportunities for research initiatives at Vanderbilt, particularly those that rely on industry partnerships.
The financial landscape for student financial aid and healthcare access could shift if the costs associated with pharmaceuticals rise, potentially affecting student enrollment and healthcare services provided by the university.

Relevance Score: 4 (The tariffs present high risks associated with financial, operational, and supply chain transformations for Vanderbilt University and its affiliates.)

Key Actions

The Vanderbilt University Medical Center (VUMC) should closely monitor the implications of the newly imposed tariffs on patented pharmaceuticals, as they may influence the cost and availability of medications essential for patient care and research. Engaging with pharmaceutical companies to understand their strategies in response to these tariffs will be crucial in mitigating risks related to drug supply disruptions.
The Department of Health and Human Services (HHS) and the Department of Commerce should be engaged to explore opportunities for Vanderbilt to enter into Most Favored Nation (MFN) pricing agreements that could qualify for a 0% tariff. This proactive approach could help secure favorable pricing for pharmaceutical products vital for research and clinical use.
The Office of Federal Relations should establish a task force to analyze the effects of the tariffs on funded research projects and explore alternative funding avenues to offset potential losses in federal grants. This will ensure that Vanderbilt remains financially stable amid changing funding landscapes.
Vanderbilt’s School of Medicine should advocate for exemptions related to specialty pharmaceutical products that could affect ongoing research, particularly those that meet urgent public health needs. This will help maintain the integrity of research initiatives and patient care programs.
The Vanderbilt Institute for Space and Defense Electronics and related departments should increase collaboration with defense and healthcare sectors to leverage the anticipated $400 billion in new investments in U.S. pharmaceutical manufacturing. This collaboration could enhance Vanderbilt’s research capabilities and funding opportunities.

Opportunities

The executive order’s emphasis on strengthening American supply chains presents a unique opportunity for Vanderbilt to expand its partnerships with pharmaceutical manufacturers and contribute to the development of a more self-sufficient domestic pharmaceutical industry.
Vanderbilt can capitalize on the changes in federal policy by enhancing its research initiatives related to domestic pharmaceutical production and supply chain resilience, potentially leading to innovative solutions that could influence national policy.
The focus on public health and national security may offer funding opportunities for Vanderbilt’s health-related research projects, especially those addressing the impacts of tariffs on access to medications and healthcare delivery.
Engaging in advocacy for policies that support the exemption of critical pharmaceutical products from tariffs can position Vanderbilt as a leader in the discourse on healthcare accessibility and pharmaceutical innovation.
The university’s commitment to research and innovation in the pharmaceutical sector could be enhanced by securing partnerships with organizations affected by the tariffs, thus fostering collaborative research efforts.

Relevance Score: 4 (The tariffs impose significant implications for Vanderbilt’s medical and research operations, necessitating major process changes to adapt to the new landscape.)

Average Relevance Score: 3

Timeline for Implementation

120 days for certain large companies
180 days for smaller companies

The shortest compliance period is 120 days, which falls into the 90-179 day category.

Relevance Score: 2

Impacted Government Organizations

Department of Commerce: The order directs the Department of Commerce to facilitate onshoring agreements and oversee tariff implementation, reflecting its central role in domestic manufacturing and trade investigations under Section 232.
Department of Health and Human Services (HHS): HHS is tasked with establishing Most Favored Nation (MFN) pricing agreements to provide tariff relief, positioning it as a key player in the administration’s strategy to balance public health and national security.

Relevance Score: 1 (A small number of agencies are impacted by the order.)

Responsible Officials

Secretary of Commerce – Led the Section 232 investigation and is responsible for overseeing and implementing onshoring agreements and related tariff measures.
Department of Commerce – Charged with establishing pathways for companies to enter into onshoring agreements as part of the tariff implementation framework.
Department of Health and Human Services – Responsible for facilitating Most Favored Nation (MFN) pricing agreements, which affect tariff exemptions.

Relevance Score: 4 (Directives impact agency heads with significant authority over trade and health policies).